Last reviewed · How we verify
RSVpreF + qIRV 1.0 mL formulation (rsvpref-qirv-1-0-ml-formulation)
At a glance
| Generic name | rsvpref-qirv-1-0-ml-formulation |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain (PAIN AT THE INJECTION SITE)
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Myalgia (NEW OR WORSENED MUSCLE PAIN)
- Chills (CHILLS)
- Arthralgia (NEW OR WORSENED JOINT PAIN)
- Catarrh
- Pyrexia (FEVER)
- Injection site swelling (SWELLING)
- Nausea (NAUSEA)
- Injection site erythema (REDNESS)
- Diarrhoea (DIARRHEA)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSVpreF + qIRV 1.0 mL formulation CI brief — competitive landscape report
- RSVpreF + qIRV 1.0 mL formulation updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI